PDCD1 and Hepatitis: Another previously published meta-analysis of 122 clinical trials reported a 0.09% mortality due to hepatitis as an irAE and 0% with an anti-CTLA-4 antibody, and 0.13% with the combination of PD-1 antibody/anti-PD-L1 antibody and an anti-CTLA-4 antibody, suggesting a non-fatal effect of combination therapies in liver damage cases [104] (Figure 7).